New COVID booster for teens shows promise in trial

NCT ID NCT06234956

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a booster shot called BIMERVAX in 242 teenagers aged 12 to 17 who had already received a different COVID-19 vaccine. The goal was to see if it safely boosts their immune protection against the virus, including the Omicron variant. Participants were followed for 12 months to monitor side effects and immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CAP Centelles

    Centelles, Barcelona, 08540, Spain

  • CAP Peralada

    Peralada, Girona, 17491, Spain

  • Hospital HM Montepríncipe

    Boadilla del Monte, Madrid, 28660, Spain

  • Hospital HM Puerta del Sur

    Móstoles, Madrid, 28938, Spain

  • Hospital Josep Trueta

    Girona, Girona, 17007, Spain

  • Hospital La Paz

    Madrid, Madrid, 28046, Spain

  • Hospital Vall Hebron

    Barcelona, Barcelona, 08035, Spain